Last reviewed 2026-05-25 · How we verify

Disamide (DISULFAMIDE)

Phase 2 active Small molecule

Disamide (generic name: DISULFAMIDE) is a disulfamide drug. It is currently in Phase 2 development.

Disulfamide works by inhibiting enzymes involved in metabolic pathways.

Disulfamide, also known as Disamide, is a small molecule drug in the disulfamide class. Its exact target and mechanism of action are unknown, but it is believed to work by inhibiting certain enzymes involved in metabolic pathways. Disulfamide is not FDA-approved for any indications, and its commercial status, including patent and generic availability, is unclear. Key safety considerations are not well-documented due to its lack of FDA approval. Further research is needed to fully understand the properties and potential uses of Disulfamide.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	DISULFAMIDE
Drug class	disulfamide
Modality	Small molecule
Therapeutic area	Metabolic
Phase	Phase 2

Mechanism of action

Think of it like a traffic cop: Disulfamide helps regulate the flow of chemicals in the body by blocking certain enzymes that control how these chemicals are processed. This can help slow down or speed up different chemical reactions, depending on the situation. By doing so, Disulfamide may help treat certain conditions, although its exact effects are still unknown.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Disamide CI brief — competitive landscape report
Disamide updates RSS · CI watch RSS

Frequently asked questions about Disamide

What is Disamide?

Disamide (DISULFAMIDE) is a disulfamide drug.

How does Disamide work?

Disulfamide works by inhibiting enzymes involved in metabolic pathways.

What is the generic name of Disamide?

DISULFAMIDE is the generic (nonproprietary) name of Disamide.

What drug class is Disamide in?

Disamide belongs to the disulfamide class. See all disulfamide drugs at /class/disulfamide.

What development phase is Disamide in?

Disamide is in Phase 2.

Drug class: All disulfamide drugs
Therapeutic area: All drugs in Metabolic

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing